Extraosseous (extramedullary) plasmacytomas: a clinicopathologic and immunophenotypic study of 32 Chinese cases

BackgroundExtraosseous plasmacytoma, so called extramedullary plasmacytoma (EMP) is relatively rare in China. The aim was investigate the clinicopathologic features of EMP and the role of Immunophenotype and genotype detection in diagnosis of EMP.MethodsThirty-two cases of EMP were investigated retrospectively by histopathology, immunophenotype, genotype and survival analysis.ResultsClinically, the mean age of the patients was 53.4. Most of the patients received no treatment after the diagnosis was established, and the prognosis was relatively poor. Histologically, in 40% of the cases, the neoplastic cells were grade II or III. The neoplastic cells expressed one or more PC associated antigens. The immunophenotype of EMP and inflammation of sinonasal regions with numerous PC infiltrations were compared and showed some difference in expression of CD45, CD27, CD44v6 and Bcl-2 as well. Ig light chain restriction was detected in 87.5% of the cases.Conclusionswe described 32 Chinese cases of EMP, compare with that reported in the literature, some differences are presented, including higher percentage of grade II and III cases, clinically inconsistent treatment and management as well as poor outcome of the disease.

[1]  Santhosh K. P. Kumar,et al.  CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations , 2005, Leukemia.

[2]  E. Low,et al.  Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma , 2004, Clinical oncology (Royal College of Radiologists (Great Britain)).

[3]  F. Zhan,et al.  CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high‐risk disease , 2003, British journal of haematology.

[4]  U. Günthert,et al.  Current Topics in Microbiology and Immunology (1993) Volume on Adhesion in Leukocyte Homing and Differentiation (eds D. Dunon, C. R. Mackay, and B. A. Imhof) CD44: a multitude of isoforms with diverse functions , 2007 .

[5]  G. Ott,et al.  Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis , 2005, The Journal of pathology.

[6]  A. Komiyama,et al.  CD27: a memory B-cell marker. , 2000, Immunology today.

[7]  G. Lockwood,et al.  Solitary extramedullary plasmacytoma of the head and neck—Long‐term outcome analysis of 68 cases , 2008, Head & neck.

[8]  R. Bartl,et al.  Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. , 1987, American journal of clinical pathology.

[9]  R. Bataille,et al.  Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. , 1995, Cancer research.

[10]  S. Rudikoff,et al.  In vitro culture of primary plasmacytomas requires stromal cell feeder layers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Bataille,et al.  Lack of CD27 in myeloma delineates different presentation and outcome , 2006, British journal of haematology.

[12]  J. Choe,et al.  Regulation of CD27 expression in the course of germinal center B cell differentiation: the pivotal role of IL‐10 , 2000, European journal of immunology.

[13]  W. Hilbe,et al.  CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma. , 2001, Leukemia research.

[14]  G Koopman,et al.  CD27-CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth. , 1995, Leukemia & lymphoma.

[15]  H. Asaoku,et al.  A possible role for the loss of CD27–CD70 interaction in myelomagenesis , 2003, British journal of haematology.

[16]  K. Vanderkerken,et al.  In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. , 2000, Cancer research.

[17]  P. Brandtzaeg,et al.  Immunoglobulin A cell distribution in the human small intestine: phenotypic and functional characteristics , 2000, Immunology.

[18]  S. Tangye,et al.  Identification of Functional Human Splenic Memory B Cells by Expression of CD148 and CD27 , 1998, The Journal of experimental medicine.

[19]  W. T. Farrington,et al.  Extramedullary plasmacytoma of the head and neck region: clinicopathological correlation in 25 cases. , 1997, British Journal of Cancer.

[20]  H. Döhner,et al.  CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. , 2005, Haematologica.

[21]  John Crowley,et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.

[22]  K. McGlynn,et al.  Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004 , 2009, British journal of haematology.

[23]  T. Okada,et al.  Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements , 1995, International journal of cancer.

[24]  W. Mendenhall,et al.  Solitary plasmacytoma of bone and soft tissues. , 2003, American journal of otolaryngology.

[25]  K. Rajewsky,et al.  Human Immunoglobulin (Ig)M+IgD+ Peripheral Blood B Cells Expressing the CD27 Cell Surface Antigen Carry Somatically Mutated Variable Region Genes: CD27 as a General Marker for Somatically Mutated (Memory) B Cells , 1998, The Journal of experimental medicine.

[26]  B. Seed,et al.  The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. , 1991, Journal of immunology.

[27]  O. Majdic,et al.  CD27 expression by a distinct subpopulation of human B lymphocytes , 1990, European journal of immunology.

[28]  D. Weber.  Solitary bone and extramedullary plasmacytoma. , 2005, Hematology. American Society of Hematology. Education Program.

[29]  R. Bataille,et al.  Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. , 2004, Haematologica.

[30]  Y. Matsuno,et al.  CD56-positive small round cell tumor: osseous plasmacytoma manifested in osteolytic tumors of the iliac bone and femora. , 2005, Japanese Journal of Clinical Oncology.

[31]  R. V. van Oers,et al.  Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. , 1994, Blood.

[32]  M. Kremer,et al.  Extramedullary plasmacytoma , 1999, Cancer.

[33]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[34]  T. Grogan,et al.  Plasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19) , 1990 .

[35]  G. Sutherland,et al.  Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor , 1993, Cell.